CD209 and neoplasm: In the same hDC-SIGN mouse model, vaccinating with a tumor-specific antigen coated with Lewis B (LeB), another glycan targeting DC-SIGN, combined with the depletion of regulatory T-cells (Treg) led to long-term regression of the tumor [13].